Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects

Istradefylline, a selective adenosine A(2A) inhibitor, is under development for the treatment of Parkinson's disease. The effect of oral steady‐state rifampin 600 mg/day, a potent cytochrome P450 (CYP) 3A4 inducer, on the disposition of a single oral dose of istradefylline 40 mg was determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Mayumi, Uchimura, Tatsuo, Zhang, Xiaoping, Greene, Douglas, Vergeire, Maria, Cantillon, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811788/
https://www.ncbi.nlm.nih.gov/pubmed/28881378
http://dx.doi.org/10.1002/jcph.1003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811788/
https://www.ncbi.nlm.nih.gov/pubmed/28881378
http://dx.doi.org/10.1002/jcph.1003

Ejemplares similares